New combo therapy aims to tackle Hard-to-Treat lung cancer
NCT ID NCT06930794
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the targeted drug vebreltinib to standard chemotherapy helps people with a specific type of advanced lung cancer (MET-positive non-squamous non-small cell lung cancer) live longer without their cancer growing. About 300 adults who have not had prior treatment will be randomly assigned to receive either the combination or chemotherapy alone. The trial is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vebreltinib (a targeted drug) combined with platinum-based chemotherapy (pemetrexed plus carboplatin or cisplatin)
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with MET-positive advanced lung cancer, potentially slowing disease progression better than chemotherapy alone.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The drug may cause side effects like those seen with other targeted therapies, and not all participants may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••